Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China

Original Submission
5 Nov 2022 Submitted Original manuscript
7 Feb 2023 Reviewed Reviewer Report
13 Apr 2023 Reviewed Reviewer Report
30 Apr 2023 Author responded Author comments - Jiaqi Ni
Resubmission - Version 2
30 Apr 2023 Submitted Manuscript version 2
2 May 2023 Author responded Author comments - Jiaqi Ni
Resubmission - Version 3
2 May 2023 Submitted Manuscript version 3
22 May 2023 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
25 May 2023 Editorially accepted
19 Jun 2023 Article published 10.1186/s12913-023-09600-7

You can find further information about peer review here.

Back to article page